BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 26559373)

  • 1. Constitutive activation of STAT3 in breast cancer cells: A review.
    Banerjee K; Resat H
    Int J Cancer; 2016 Jun; 138(11):2570-8. PubMed ID: 26559373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer.
    Alshaker H; Wang Q; Frampton AE; Krell J; Waxman J; Winkler M; Stebbing J; Cooper C; Yagüe E; Pchejetski D
    Breast Cancer Res Treat; 2015 Jan; 149(1):59-67. PubMed ID: 25481644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.
    Siersbæk R; Scabia V; Nagarajan S; Chernukhin I; Papachristou EK; Broome R; Johnston SJ; Joosten SEP; Green AR; Kumar S; Jones J; Omarjee S; Alvarez-Fernandez R; Glont S; Aitken SJ; Kishore K; Cheeseman D; Rakha EA; D'Santos C; Zwart W; Russell A; Brisken C; Carroll JS
    Cancer Cell; 2020 Sep; 38(3):412-423.e9. PubMed ID: 32679107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
    Johnson DE; O'Keefe RA; Grandis JR
    Nat Rev Clin Oncol; 2018 Apr; 15(4):234-248. PubMed ID: 29405201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer.
    Haviland R; Eschrich S; Bloom G; Ma Y; Minton S; Jove R; Cress WD
    PLoS One; 2011; 6(10):e24923. PubMed ID: 22046235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terpenoid-Mediated Targeting of STAT3 Signaling in Cancer: An Overview of Preclinical Studies.
    Khan F; Pandey P; Verma M; Upadhyay TK
    Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of p68 and STAT3 synergistically diminishes cancer progression.
    Hashemi V; Ahmadi A; Malakotikhah F; Chaleshtari MG; Baghi Moornani M; Masjedi A; Sojoodi M; Atyabi F; Nikkhoo A; Rostami N; Baradaran B; Azizi G; Yousefi B; Ghalamfarsa G; Jadidi-Niaragh F
    Life Sci; 2020 May; 249():117499. PubMed ID: 32142763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.
    Adesoye T; Tripathy D; Hunt KK; Keyomarsi K
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.
    Hu Y; Dong Z; Liu K
    J Exp Clin Cancer Res; 2024 Jan; 43(1):23. PubMed ID: 38245798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.
    Zhou X; Zhao J; Yan T; Ye D; Wang Y; Zhou B; Liu D; Wang X; Zheng W; Zheng B; Qian F; Li Y; Li D; Fang L
    Cell Death Dis; 2024 Apr; 15(4):260. PubMed ID: 38609357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy.
    Garg M; Shanmugam MK; Bhardwaj V; Goel A; Gupta R; Sharma A; Baligar P; Kumar AP; Goh BC; Wang L; Sethi G
    Med Res Rev; 2020 Dec; ():. PubMed ID: 33289118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Signal Transducer and Activator of Transcription 3 (STAT3) to Bone Development and Repair.
    Sobah ML; Liongue C; Ward AC
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major Functional Transcriptome of an Inferred Center Regulator of an ER(-) Breast Cancer Model System.
    Liu LY; Chang LY; Kuo WH; Hwa HL; Lin YS; Huang SF; Chen CN; Chang KJ; Hsieh FJ
    Cancer Inform; 2012; 11():87-111. PubMed ID: 22553414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
    Aleskandarany MA; Agarwal D; Negm OH; Ball G; Elmouna A; Ashankyty I; Nuglozeh E; Fazaludeen MF; Diez-Rodriguez M; Nolan CC; Tighe PJ; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Feb; 156(1):9-20. PubMed ID: 26907764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
    McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
    Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 signaling in immunity.
    Hillmer EJ; Zhang H; Li HS; Watowich SS
    Cytokine Growth Factor Rev; 2016 Oct; 31():1-15. PubMed ID: 27185365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
    Furtek SL; Backos DS; Matheson CJ; Reigan P
    ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism.
    Zhao C; Li H; Lin HJ; Yang S; Lin J; Liang G
    Trends Pharmacol Sci; 2016 Jan; 37(1):47-61. PubMed ID: 26576830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
    Kim BH; Yi EH; Ye SK
    Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
    Geiger JL; Grandis JR; Bauman JE
    Oral Oncol; 2016 May; 56():84-92. PubMed ID: 26733183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.